Abstract:Salsolinol (SAL), i.e.1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroiso-quinoline, is a dopamine metabolite and endogenous neurotoxin that is toxic to dopaminergic neurons, and is involved in the genesis of Parkinson's disease (PD). However, the machinery underlying SAL induces neurotoxicity in PD are still being elucidated. In the present study, we first used RNA sequencing (RNAseq) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to detect differentially expressed genes in SAL-treated SH-SY5Y cells. We found that ferroptosis-related pathway was enriched by SAL, which was validated by in vitro and in vivo SAL models. SAL inducing ferroptosis through downregulating SLC7A11/GPX4 in SH-SY5Y cells, which neurotoxic effect was reversed by ferroptosis inhibitors deferoxamine (DFO) and ferrostatin-1 (Fer-1). Acteoside, a phenylethanoid glycoside of plant origin with neuroprotective effect, attenuates SAL-induced neurotoxicity by inhibiting ferroptosis in in vitro and in vivo PD models through upregulating SLC7A11/GPX4. Mechanistically, acteoside activates Nrf2. Nrf2 inhibitor ML385 abolished acteoside-mediated increased SLC7A11/GPX4 and neuroprotection against SAL in SH-SY5Y cells. Meanwhile, the PI3K inhibitor LY294002 suppressed the acteoside-induced Nrf2 expression and ensued decreased expression of SLC7A11/GPX4 in SAL-treated SH-SY5Y cells. Taken together, these results demonstrate that salsolinol-induced PD through inducing ferroptosis via downregulating SLC7A11/GPX4. Acteoside attenuates SAL-induced PD through inhibiting ferroptosis via activating PI3K/Akt-dependant Nrf2. The present study revealed a novel molecular mechanisms underlining SAL-induced neurotoxicity via induction of ferroptosis in PD, and uncovered a new pharmacological effect against PD through inhibiting ferroptosis. This study highlights SAL-induced ferroptosis -dependent neurotoxicity as a potential therapeutic target in PD.

Salidroside protects PC12 cells from MPP⁺-induced apoptosis via activation of the PI3K/Akt pathway.

Salidroside protected against MPP + -induced Parkinson's disease in PC12 cells by inhibiting inflammation, oxidative stress and cell apoptosis.

Salidroside Protects Dopaminergic Neurons by Regulating the Mitochondrial MEF2D-ND6 Pathway in the MPTP/MPP+ -Induced Model of Parkinson's Disease.

Neuroprotective effect of salidroside against 6-OHDA-induced oxidative stress in PC12 cells

Salidroside inhibits H2O2-induced apoptosis in PC12 cells by preventing cytochrome c release and inactivating of caspase cascade.

Salidroside Protects SH‑SY5Y from Pathogenic Α‑synuclein by Promoting Cell Autophagy Via Mediation of Mtor/p70s6k Signaling.

Salidroside Protects Against 6-Hydroxydopamine-induced Cytotoxicity by Attenuating ER Stress

[Salidroside Protects PC12 Cells from H2O2-induced Apoptosis Via Suppressing NOX2-ROS-MAPKs Signaling Pathway].

Salsolinol Induces Parkinson's Disease Through Activating NLRP3-Dependent Pyroptosis and the Neuroprotective Effect of Acteoside

Salidroside Ameliorates Parkinson's Disease by Inhibiting NLRP3-dependent Pyroptosis

Salvianolic Acid B Protects SH-SY5Y Neuroblastoma Cells from 1-Methyl-4-phenylpyridinium-induced Apoptosis.

Salidroside Inhibits H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;-induced Apoptosis in PC 12 Cells by Preventing Cytochrome &lt;italic&gt;c&lt;/italic&gt; Release and Inactivating of Caspase Cascade

Acteoside Alleviates Salsolinol-Induced Parkinson's Disease by Inhibiting Ferroptosis Via Activating Nrf2/SLC7A11/GPX4 Pathway

Salidroside inhibits H<sub>2</sub>O<sub>2</sub>-induced apoptosis in PC 12 cells by preventing cytochrome<i>c</i>release and inactivating of caspase cascade

Salidroside improves cognitive function in Parkinson's disease via Braf-mediated mitogen‐activated protein kinase signaling pathway

Neuroprotective Effects of Salidroside in the PC12 Cell Model Exposed to Hypoglycemia and Serum Limitation

Effect of Salidroside on PI3K/protein kinase B signaling in Parkinson's disease model mice

Salvianolic acid B protects against MPP+-induced neuronal injury via repressing oxidative stress and restoring mitochondrial function

Salidroside Promotes the Pathological Α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells

Salidroside Improves Brain Ischemic Injury by Activating PI3K/Akt Pathway and Reduces Complications Induced by Delayed Tpa Treatment.

Salidroside inhibited cerebral ischemia/reperfusion-induced oxidative stress and apoptosis via Nrf2/Trx1 signaling pathway